Similarly, CYP1B1*3 polymorphisms & its association with adryamycin and paclitaxel based chemotherapy noted negativeassociation with protective effects of CYP1B1 (rs1056836) with MCO (OR=0.14, 95% CI: 0.03-0.54; p=0.004) in doxorubicin basedchemotherapy and peripheral neuropathy in paclitaxel based chemotherapy in BC-P (OR=0.41, 95% CI: 0.17-0.96; p=0.040). Here, CYP1B1 is linked to peripheral neuropathy.